MicroBiome Therapeutics, LLC, a New Orleans, La.-based company applying the science of the gastrointestinal (GI) microbiome to promote health and wellness, completed a $1m Series B financing.
Backers included Lagniappe Angels, NO/LA Angel Network, Zehnder Communications and other private investors. In conjunction with the funding, Jeremy Hunnewell, CFO and Business Strategist for Zehnder Communications, will be joining the board of directors of MBT.
The company intends to use the funds to launch its clinically-tested microbiome modulator product in 2018.
Led by Dale Pfost, Acting CEO, MicroBiome is advancing a dietary supplement specifically designed to balance and optimize the GI tract. The product is an all-natural blend of prebiotics, including fermentable fiber and polyphenol antioxidants in a patent-pending blend intended to help nurture and nourish beneficial microorganisms in the lower gut.
It has been tested in two clinical trials and will be launched in 2018.